NLTX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 gruod. 2023 @ 23:00):

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology...

Stats
Dzisiejszy wolumen	109 095
Średni wolumen	5 520.00
Kapitalizacja rynkowa	8.20M
EPS	$0 ( 2024-03-19 )
Następna data zysków	( $0 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.284
ATR14	$0.878 (25.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-16	Woods Robert Keith	Buy	15 400	Stock Option (Right to Buy)
2024-01-16	Palekar Rohan	Buy	15 400	Stock Option (Right to Buy)
2024-01-16	Noonberg Sarah B.	Buy	15 400	Stock Option (Right to Buy)
2024-01-16	Freedland Cory S.	Buy	15 400	Stock Option (Right to Buy)
2024-01-16	Baffi Robert	Buy	15 400	Stock Option (Right to Buy)

INSIDER POWER
75.00
Last 94 transactions
Buy: 7 989 742 \| Sell: 1 025 638

Wolumen Korelacja

Długi: -0.32 (neutral)

Krótki: -0.52 (weak negative)

Signal:(16.09) Neutral

Neoleukin Therapeutics Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Neoleukin Therapeutics Korelacja - Waluta/Towar

-0.04
( neutral )

0.06
( neutral )

-0.14
( neutral )

0.10
( neutral )

-0.16
( neutral )

-0.18
( neutral )

Neoleukin Therapeutics Finanse

Annual	2022
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-1.010

FY	2022
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-1.010

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-1.100

FY	2020
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.640

Financial Reports:

No articles found.

Neoleukin Therapeutics

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.